These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35566268)

  • 1. Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex.
    Deval J; Gurard-Levin ZA
    Molecules; 2022 May; 27(9):. PubMed ID: 35566268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
    Tahir M
    J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.
    Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
    Robson F; Khan KS; Le TK; Paris C; Demirbag S; Barfuss P; Rocchi P; Ng WL
    Mol Cell; 2020 Sep; 79(5):710-727. PubMed ID: 32853546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA.
    Moeller NH; Passow KT; Harki DA; Aihara H
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
    Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification.
    Baddock HT; Brolih S; Yosaatmadja Y; Ratnaweera M; Bielinski M; Swift LP; Cruz-Migoni A; Fan H; Keown JR; Walker AP; Morris GM; Grimes JM; Fodor E; Schofield CJ; Gileadi O; McHugh PJ
    Nucleic Acids Res; 2022 Feb; 50(3):1484-1500. PubMed ID: 35037045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors.
    Riccio AA; Sullivan ED; Copeland WC
    J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.
    Smith EC; Blanc H; Surdel MC; Vignuzzi M; Denison MR
    PLoS Pathog; 2013 Aug; 9(8):e1003565. PubMed ID: 23966862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of nsp14 Exonuclease from SARS-CoV-2 towards RNAs with Modified 3'-Termini.
    Yuyukina SK; Barmatov AE; Bizyaev SN; Stetsenko DA; Sergeeva OV; Zatsepin TS; Zharkov DO
    Dokl Biochem Biophys; 2023 Apr; 509(1):65-69. PubMed ID: 37340295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution and functional characterization of SARS-CoV-2 proofreading complex.
    Ma Z; Pourfarjam Y; Kim IK
    Protein Expr Purif; 2021 Sep; 185():105894. PubMed ID: 33933612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN.
    Moeller NH; Shi K; Demir Ö; Belica C; Banerjee S; Yin L; Durfee C; Amaro RE; Aihara H
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35165203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations.
    Graepel KW; Lu X; Case JB; Sexton NR; Smith EC; Denison MR
    mBio; 2017 Nov; 8(6):. PubMed ID: 29114026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The coronavirus proofreading exoribonuclease mediates extensive viral recombination.
    Gribble J; Stevens LJ; Agostini ML; Anderson-Daniels J; Chappell JD; Lu X; Pruijssers AJ; Routh AL; Denison MR
    PLoS Pathog; 2021 Jan; 17(1):e1009226. PubMed ID: 33465137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.
    Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG
    FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
    Pearson LA; Green CJ; Lin D; Petit AP; Gray DW; Cowling VH; Fordyce EAF
    SLAS Discov; 2021 Jul; 26(6):749-756. PubMed ID: 33724070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.
    Scholle MD; Liu C; Deval J; Gurard-Levin ZA
    SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target.
    Rona G; Zeke A; Miwatani-Minter B; de Vries M; Kaur R; Schinlever A; Garcia SF; Goldberg HV; Wang H; Hinds TR; Bailly F; Zheng N; Cotelle P; Desmaële D; Landau NR; Dittmann M; Pagano M
    Cell Death Differ; 2022 Feb; 29(2):285-292. PubMed ID: 34862481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of the EpiMed Coronabank Chemical Collection to identify potential SARS-CoV-2 antivirals: in silico studies targeting the nsp14 ExoN domain and PL
    Liang JJ; Pitsillou E; Lau HLY; Mccubbery CP; Gan H; Hung A; Karagiannis TC
    J Mol Graph Model; 2024 Sep; 131():108803. PubMed ID: 38815531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.